A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

PHASE2CompletedINTERVENTIONAL

Enrollment

420

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions

Migraine

Interventions

DRUG

Comparator: Placebo

Placebo to match assigned treatment arm; one orally-administered dose

DRUG

MK0974

MK0974 25 mg; one orally-administered dose

DRUG

MK0974

MK0974 50 mg; one orally-administered dose

DRUG

MK0974

MK0974 100 mg; one orally-administered dose

DRUG

MK0974

MK0974 200 mg; one orally-administered dose

DRUG

MK0974

MK0974 300 mg; one orally-administered dose

DRUG

MK0974

MK0974 400 mg; one orally-administered dose

DRUG

MK0974

MK0974 600 mg; one orally-administered dose

DRUG

Rizatriptan

Rizatriptan 10 mg; one orally-administered dose

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00246337 - A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004) | Biotech Hunter | Biotech Hunter